From 2016 to 2019, the volume of literature grew slowly in both areas, but the number of studies on “pyroptosis in PD” was higher than that on “ferroptosis in PD.” From 2020 to 2021, the research on “pyroptosis in PD” grew rapidly, while the research on “ferroptosis in PD” grew more slowly, indicating that “pyroptosis in PD” was the hotspot of the research in this stage, and the research focused on the development of a variety of PD therapeutics targeting molecules involved in the NLRP3 inflammatory pathway and the pyroptosis pathway, and much progress had been made in this phase. The gene discussed is NLRP3; the disease is Parkinson disease.